Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation

Gastroenterology

Volumn 132, Issue 3, 2007, Pages 931-937

  Gane, Edward J ^a   Angus, Peter W ^b   Strasser, Simone ^c   Crawford, Darrell H G ^d   Ring, John ^e   Jeffrey, Gary P ^f   McCaughan, Geoffrey W ^c  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b AUSTIN HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PREDNISONE; TACROLIMUS; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KAPLAN MEIER METHOD; LIVER DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SURVIVAL; TREATMENT DURATION; VIRUS TITRATION; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; AUSTRALIA; DISEASE-FREE SURVIVAL; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; INJECTIONS, INTRAMUSCULAR; KAPLAN-MEIERS ESTIMATE; LAMIVUDINE; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEW ZEALAND; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947304026     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.01.005     Document Type: Article

References (37)

1. O'Grady J., Smith H., Davies S., Daniels H., Donaldson P., Tan K., Portmann B., and Williams R. Hepatitis B re-infection after orthotopic liver transplantation-serologic and clinical implications. J Hepatol 14 (1992) 104-111
2. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., and Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
3. Terrault N., Zhou S., Combs C., Hahn J.A., Lake J.R., Roberts J.P., Ascher N.L., and Wright T.L. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24 (1996) 1327-1333
4. McGory R., Ishitani M., Oliveira W., Stevenson W., McCullough C., Dickson R., Caldwell S., and Pruett T. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunisation. Transplantation 61 (1996) 1358-1363
5. Nery J., Weppler D., Rodriguez M., Ruiz P., Schiff E., and Tzakis A. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65 (1998) 1615-1621
6. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A., Rolles K., McMaster P., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212-1215
7. Mutimer D., Dusheiko G., Barrett C., Grellier L., Ahmed M., Anschuetz G., et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 70 (2000) 809-815
8. Perrillo R., Wright T., Rakela J., Levy G., Schiff E., Gish R., et al. A multicentre United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
9. Lo C., Cheung S., Lai C., Liu C., Ng I., Yuen M., Fan S., and Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 233 (2001) 276-281
10. Markowitz J., Martin P., Conrad J.A., Markmann J., Seu P., Yersiz H., Goss J., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination of lamivudine plus hepatitis B immunoglobulin. Hepatology 28 (1998) 585-589
11. Sugawara Y., Makuuchi M., Kaneko J., Akamatsu N., Imamura H., and Kokudo N. Living donor liver transplantation for hepatitis B cirrhosis. Liver Transplant 9 (2003) 1181-1184
12. Gane E., McCall J., Streat S., and Munn S. Liver transplantation in New Zealand-the first 4 years. N Z Med J 115 (2002) 1156-1159
13. McCaughan G., Spencer J., Koorey D., Bowden S., Bartholomeusz A., Littlejohn M., Verran D., et al. Lamivudine therapy in patients undergoing liver transplantation for HBV precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose HBIG. Liver Transplant 5 (1999) 512-519
14. Angus P., McCaughan G., Gane E., Crawford D., Harley H., and Jeffrey G. Combination low-dose HBIG and lamivudine provides effective prophylaxis against post-transplantation hepatitis B. Liver Transplant 6 (2000) 429-433
15. 26th Report of the Australian and New Zealand Liver Transplant Registry, 2003. Available at: http://www.anzdata.org.au. Accessed August 10, 2005.
16. Roche B., Feray C., Gigou M., Roque-Afonso A., Arulnaden J., Delvart V., Dussaix E., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 38 (2003) 86-95
17. Shouval D., and Samuel D. HBIG to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
18. Burbach G., Bienzle U., Neuhaus R., Hopf U., Metzger W., Pratschke J., and Neuhaus P. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of HBV reinfection after orthotopic liver transplantation. Transplantation 63 (1997) 478-480
19. Seehofer D., Rayes N., Maumann U., Neuhaus R., Muller A., Tullius S., et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV DNA+ patients undergoing liver transplantation. Transplantation 72 (2001) 1381-1385
20. Bock C., Tillmann H., Torresi J., Klempnauer J., Locarnini S., Manns M., and Trautwein C. Selection of HBV polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122 (2002) 264-273
21. Terrault N., Zhou S., McCory R., Pruett T., Lake J., Ascher N.L., and Wright T.L. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28 (1998) 555-561
22. Ahmed S., Tavan D., Pichoud C., Berby F., Stuyver L., Johnson M., et al. Early detection of viral resistance by determination of HBV polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32 (2000) 1078-1088
23. Yuen M., Sablon E., Hui C., Yuan H., Decraemer H., and Lai C. Factors as associated with HBV DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34 (2001) 785-791
24. Mutimer D., Pillay D., Dragon E., Tang H., Ahmed M., O'Donnell K., Shaw J., et al. High pretreatment hepatitis B viral titre predicts failure of lamivudine prophylaxis and graft reinfection after liver transplantation. J Hepatol 30 (1999) 715-721
25. Leung N., Lai C., Chang T., Guan R., Lee C., Ng K., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
26. Zollner B., Petersen J., Schroter M., Laufs R., Schoder V., and Feucht H. 20-Fold increase of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357 (2001) 934
27. Kao J., Liu C., and Chen D. Hepatitis B genotypes and lamivudine resistance. J Hepatol 36 (2002) 303-305
28. Akuta N., Suzuki F., Kobayashi M., Tsubota A., Suzuki Y., Hosaka T., Someya T., et al. Influence of HBV genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 38 (2003) 315-322
29. Devarbhavi H., Cohen A., Patel R., Wiesner R., Dickson R., and Ishitani M. Preliminary results: outcome of liver transplantation for hepatitis B varies by HBV genotype. Liver Transplant 8 (2002) 550-555
30. Zollner B., Petersen J., Puchhammer E., Kletzmayr J., Sterneck M., Fischer L., Schroter M., et al. Viral features of lamivudine-resistant hepatitis B genotypes A and D. Hepatology 39 (2004) 42-50
31. Mutimer D., Pillay D., Shields P., Cane P., Ratcliffe D., Martin B., et al. The real danger of lamivudine resistant HBV infection in the immunocompromised host. Gut 46 (2000) 107-113
32. de Man R., Bartholomeusz A., Niesters H., Zondervan P., and Locarnini S. Sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B. J Hepatol 29 (1998) 669-675
33. Naoumov N., Lopes A., Burra P., Caccamo L., Iemmolo R., de Man R., Bassendine M., et al. Randomised trial of lamivudine versus HBIG for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 34 (2001) 888-894
34. Lo C., Fung J., Lau G., Liu C., Cheung S., Fan S., and Wong J. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 37 (2003) 36-43
35. Sanchez-Fueyo A., Rimola A., Grande L., Costa J., Mas A., Navasa M., Cirera I., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B vaccination. Hepatology 31 (2000) 496-501
36. Bienzle U., Gunther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., and Neuhaus P. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B related disease. Hepatology 38 (2003) 811-819
37. Angelico M., di Paolo D., Trinito M., Petrolatui A., Araco A., Zazza S., Lionetti R., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35 (2002) 176-181